Your fact-checks will appear here
US FDA supporting computerized database
Certain medications can be associated with , but the strength of evidence varies by drug class: the strongest, most consistently reported signals involve 5‑alpha‑reductase inhibitors (finasteride, dut...
Tirzepatide (Mounjaro, Zepbound) primarily raises concern for pharmacodynamic interactions that increase hypoglycaemia risk when combined with other glucose‑lowering drugs — especially insulin and sul...
Clinical trials and pooled analyses consistently identify gastrointestinal effects — especially nausea, diarrhea, vomiting and constipation — as the most common adverse reactions to tirzepatide, while...
Herbal ingredients commonly found in "Memory Blast"–style supplements — notably Bacopa monnieri and Ginkgo biloba — have mixed evidence on benefits and known safety signals: randomized trials and syst...
No publicly available sources in the provided reporting name or describe “garaherb” specifically, so direct, product-level adverse-event counts for garaherb cannot be reported from these documents; in...
The materials provided do not contain independent clinical trials or standalone adverse-event reports for a product named "Karylief"; instead, reporting focuses on Karyopharm’s clinical programs for c...
Post-marketing pharmacovigilance analyses of tirzepatide identify disproportionate reporting for pancreato-biliary events (including pancreatitis), thyroid-related events, and eye-related events acros...
Real‑world pharmacovigilance and observational studies consistently identify gastrointestinal events—nausea, vomiting, diarrhea, constipation and dyspepsia—as the most common adverse events (AEs) with...
Serious adverse reactions reported with ivermectin include neurologic events (encephalopathy, confusion, coma), severe cutaneous reactions (Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS)...
Available sources reviewed do not mention any postmarket adverse reactions specific to a product named "Lipoless"; the supplied documents describe how postmarketing surveillance systems work and what ...
Available reporting and public databases in the provided results do not show any regulatory safety warnings or new contraindications specifically for a product named “Gelatide” in 2025; consumer-facin...
Available reporting shows no clear U.S. FDA approval or official FDA safety warning specifically for a consumer brain supplement called “Neurocept”; most hits are commercial reviews, vendor pages and ...
Neurocept is presented in consumer press as an over‑the‑counter brain‑health supplement with no published, product‑level clinical trials in the provided sources, while aducanumab and lecanemab are pre...
Available reporting on "Neurocept" is fragmented and inconsistent: product pages and supplement marketing claim “no known harmful side effects” and safety for long‑term use , while independent drug in...
There are no postmarketing surveillance reports for a drug named “neurogold” in the provided sources; available sources describe how postmarketing surveillance works, not specific adverse events for t...
Available reporting and regulator pages in the provided search results do not mention any FDA or EMA legal actions, safety notices, drug alerts, or communications specifically referencing a product na...
The available materials provide that Neurocept underwent a 2023 clinical trial reporting age‑specific adverse reactions in older adults; the documents reviewed are marketing pages, product listings, a...
There are no documented, specific reports of dangerous drug interactions attributed to a product called "Lipomax" in the provided 2020–2025 materials; regulatory signal reports and FAERS summaries rev...
Dr. Sanjay Gupta’s public statements linking Neurocept (and related neurotherapies like NeuroEPO/NeuroAiD) to cognitive benefit rest on a mix of that some neuroactive compounds can affect brain health...